Blincyto (Blinatumomab) Medicine

HomeBlincyto (Blinatumomab) Medicine

 

Medical Evidence blincyto

Generic name : Blinatumomab.

Trade name : Blincyto.

Manufacturer information :

Blincyto is manufactured by Amgen Inc.

Blincyto FDA Approval:

Blincyto first approved December 3rd, 2014.

Dosage form :

For injection: 35 mcg of lyophilized powder in a single-use vial for reconstitution.

Blincyto Indications and Usage :

Acute Lymphoblastic Leukemia

Indicated for Philadelphia chromosome-negative relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL).

 

Blincyto (Blinatumomab) availability in India

  • You could import this medicine against import permit on Patient Name.
  • Please contact ACT Lifesciences Private Limited for further information.